Congenital thrombotic thrombocytopenic purpura
Jump to navigation
Jump to search
| Section editor | |
|---|---|
 |
Benjamin Tillman, MD Vanderbilt University Nashville, TN, USA |
- We have moved How I Treat articles to a dedicated page.
| Last updated on 2024-07-23: 1 regimens on this page
1 variants on this page
|
All lines of therapy
rADAMTS13 monotherapy
Regimen
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Scully et al. 2024 (cTTP) | 2010-10 to 2014-01 | Phase 3 (E-switch-ooc) | Standard treatment | No acute TTP events |
Supportive therapy
References
- cTTP: Scully M, Antun A, Cataland SR, Coppo P, Dossier C, Biebuyck N, Hassenpflug WA, Kentouche K, Knöbl P, Kremer Hovinga JA, López-Fernández MF, Matsumoto M, Ortel TL, Windyga J, Bhattacharya I, Cronin M, Li H, Mellgård B, Patel M, Patwari P, Xiao S, Zhang P, Wang LT; cTTP Phase 3 Study Investigators. Recombinant ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura. N Engl J Med. 2024 May 2;390(17):1584-1596. link to original article PubMed NCT03393975